柳树皮提取物在人肝细胞样HepaRG细胞中的药物相互作用潜力、细胞毒性与活性氧产生
本研究用两种柳树皮提取物(S6与B)处理人肝细胞样HepaRG细胞,评估CYP450酶活性调节、细胞毒性与活性氧产生。两种提取物均未明显降低细胞活力或增加ROS,但在≥25 μg/ml时降低CYP1A2和CYP3A4活性(仅S6具统计学显著性),并抑制CYP2C19活性。结论提示较高浓度下柳树皮提取物有药物相互作用潜力,且两种提取物强度不同。
要点
- 两种柳树皮提取物在HepaRG细胞中未显示明显细胞毒性或ROS增加。
- ≥25 μg/ml时降低CYP1A2和CYP3A4活性,仅S6提取物具统计学显著性。
- ≥25 μg/ml时还抑制CYP2C19活性,S6在25 μg/ml处理48h抑制mRNA表达。
核心结论
- 较高浓度的柳树皮提取物显示药物相互作用潜力,但两种提取物强度不同。
- 鉴于多药联用普遍,尤其老年慢性疼痛患者,需进一步系统研究柳属物种以准确评估药物相互作用风险。
研究设计与样本
- 采用人肝细胞样HepaRG细胞进行体外实验,评估两种柳树皮提取物对CYP450酶活性、细胞毒性和ROS产生的影响。
- 提取物S6(S. pentandra,含总水杨酸盐8.15 mg/ml和柳苷0.08 mg/ml)与提取物B(工业参考品,含总水杨酸盐5.35 mg/ml和柳苷2.26 mg/ml),均标准化至10 mg/ml酚类含量。
主要发现
- 两种提取物均未导致细胞活力相关降低或ROS产生增加。
- 处理48小时后,≥25 μg/ml时降低CYP1A2和CYP3A4酶活性,仅S6具统计学显著性。
- ≥25 μg/ml时观察到CYP2C19活性抑制(0.5小时),S6在25 μg/ml处理48小时抑制mRNA表达。
临床怎么用
- 临床使用柳树皮提取物时,对经CYP1A2、CYP3A4或CYP2C19代谢的药物需关注潜在相互作用,尤其高浓度或长期使用。
- 老年慢性疼痛患者多药联用时,应评估柳树皮制剂的药物相互作用风险。
局限性
- 研究为体外细胞实验,结果外推到临床需谨慎。
- 仅测试两种提取物,不同柳属物种或提取工艺的相互作用潜力可能不同。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Herbal preparations of willow bark (Salix cortex) are available in many countries as non-prescription medicines for pain and inflammation, and also as dietary supplements. Currently only little information on toxicity and drug interaction potential of the extracts is available. This study now evaluated the effects of two Salix cortex extracts on human hepatocyte-like HepaRG cells, in view of clinically relevant CYP450 enzyme activity modulation, cytotoxicity and production of reactive oxygen species (ROS). Drug metabolism via the CYP450 enzyme system is considered an important parameter for the occurrence of drug-drug interactions, which can lead to toxicity, decreased pharmacological activity, and adverse drug reactions. We evaluated two different bark extracts standardized to 10 mg/ml phenolic content. Herein, extract S6 (S. pentandra, containing 8.15 mg/ml total salicylates and 0.08 mg/ml salicin) and extract B (industrial reference, containing 5.35 mg/ml total salicylates and 2.26 mg/ml salicin) were tested. Both Salix cortex extracts showed no relevant reduction in cell viability or increase in ROS production in hepatocyte-like HepaRG cells. However, they reduced CYP1A2 and CYP3A4 enzyme activity after 48 h at ≥25 μg/ml, this was statistically significant only for S6. CYP2C19 activity inhibition (0.5 h) was also observed at ≥25 μg/ml, mRNA expression inhibition by 48 h treatment with S6 at 25 μg/ml. In conclusion, at higher concentrations, the tested Salix cortex extracts showed a drug interaction potential, but with different potency. Given the high prevalence of polypharmacy, particularly in the elderly with chronic pain, further systematic studies of Salix species of medical interest should be conducted in the future to more accurately determine the risk of potential drug interactions.
引用
- Gomes JVD, Herz C, Helmig S, et al. Drug-Drug Interaction Potential, Cytotoxicity, and Reactive Oxygen Species Production of Salix Cortex Extracts Using Human Hepatocyte-Like HepaRG Cells. Front Pharmacol. 2021. PMID: 34867410. doi:10.3389/fphar.2021.779801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。